YUHSpace: FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

YUHSpace

BROWSE

18 76

Cited 0 times in

Cited 0 times in

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Authors: Alexander Spira ; Byoung Chul Cho ; Enriqueta Felip ; Edward B Garon ; Koichi Goto ; Melissa Johnson ; Natasha Leighl ; Antonio Passaro ; David Planchard ; Sanjay Popat ; James Chih-Hsin Yang ; Xiaoqian Lu ; Yong Jiang ; Jack Huang ; Morgan Lam ; Marcin Kowanetz ; Shirley Wang ; John Le ; Jerry Y Hsu ; Cai-Cun Zhou

Citation: LUNG CANCER, Vol.199 : 108066, 2025-01

Journal Title: LUNG CANCER

ISSN: 0169-5002

Issue Date: 2025-01

Keywords: Advanced ; EGFR ; EGFR-TKI ; Ex20ins ; Exon 20 insertions ; Firmonertinib ; Furmonertinib ; Metastatic

Files in This Item:: T202503388.pdf Download

DOI: 10.1016/j.lungcan.2024.108066

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Cho, Byoung Chul(조병철) https://orcid.org/0000-0002-5562-270X

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/206169

사서에게 알리기

Show full item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

License

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links